APA (7th ed.) Citation

Torasawa, M., Yoshida, T., Takeyasu, Y., Shimoda, Y., Tateishi, A., Matsumoto, Y., . . . Ohe, Y. (2023). Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients. Cancer Medicine, 12(11), 12388. https://doi.org/10.1002/cam4.5939

Chicago Style (17th ed.) Citation

Torasawa, Masahiro, et al. "Disease Progression Status During Initial Immune Checkpoint Inhibitor (ICI) Affects the Clinical Outcome of ICI Retreatment in Advanced Non‐small Cell Lung Cancer Patients." Cancer Medicine 12, no. 11 (2023): 12388. https://doi.org/10.1002/cam4.5939.

MLA (9th ed.) Citation

Torasawa, Masahiro, et al. "Disease Progression Status During Initial Immune Checkpoint Inhibitor (ICI) Affects the Clinical Outcome of ICI Retreatment in Advanced Non‐small Cell Lung Cancer Patients." Cancer Medicine, vol. 12, no. 11, 2023, p. 12388, https://doi.org/10.1002/cam4.5939.